Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z diagnozą chłoniaka z dużych komórek B (potwierdzoną badaniem histopatologicznym).
- •Pacjenci, którzy ukończyli pełne leczenie pierwszej linii (np. R-CHOP) zgodnie z planem.
- •Pacjenci, u których po leczeniu pierwszej linii uzyskano całkowitą lub częściową odpowiedź na leczenie, a następnie wykryto chorobę resztkową (MRD).
- •Pacjenci, którzy ukończyli 18 lat.
- •Pacjenci w dobrym ogólnym stanie zdrowia, mogący wykonywać codzienne czynności (stan sprawności ECOG 0 lub 1).
- •Pacjenci z wystarczająco dobrą funkcją krwi, nerek, wątroby, płuc i serca.
- •Dolegliwości niezwiązane z krwią, które wystąpiły po wcześniejszym leczeniu, muszą ustąpić lub być łagodne.
✗ Disqualifies
- •Chłoniak z zajęciem ośrodkowego układu nerwowego, chłoniak, który przekształcił się z innej choroby lub specyficzne typy chłoniaków.
- •Wcześniejsze leczenie ukierunkowane na antygen CD19.
- •Aktywne leczenie przeciwnowotworowe (w tym radioterapia) po zakończeniu leczenia pierwszej linii.
- •Ciężkie, aktywne choroby autoimmunologiczne.
- •Aktywne, poważne infekcje bakteryjne, grzybicze lub wirusowe wymagające leczenia ogólnego.
- •Inne choroby nowotworowe lub choroby szpiku kostnego w ciągu ostatnich 3 lat.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (77)
Banner MD Anderson Cancer Center
Gilbert, United States
Genesis Cancer and Blood Institute
Hot Springs, United States
Alta Bates Summit Medical Center
Berkeley, United States
City of Hope
Duarte, United States
Cedars-Sinai Medical Center
Los Angeles, United States
University of California, Los Angeles
Los Angeles, United States
University of California, Davis Comprehensive Cancer Center
Sacramento, United States
University of California, San Diego
San Diego, United States
University of California, San Francisco
San Francisco, United States
Rocky Mountain Cancer Centers
Denver, United States
Medical Oncology Hematology Consultants
Newark, United States
MedStar Georgetown University Hospital
Washington D.C., United States
Miami Cancer Institute at Baptist Health, Inc.
Miami, United States
Advent Health Cancer Institute
Orlando, United States
Orlando Health Cancer Institute
Orlando, United States
Moffitt Cancer Center
Tampa, United States
Augusta University Georgia Cancer Center
Augusta, United States
Northwestern University - Feinberg School of Medicine
Chicago, United States
Rush University Medical Center
Chicago, United States
Fort Wayne Medical Oncology and Hematology
Fort Wayne, United States
IU Simon Comprehensive Cancer Center
Indianapolis, United States
Indiana Blood and Marrow Transplantation
Indianapolis, United States
The University of Kansas Hospital
Kansas City, United States
University of Kentucky Medical Center
Lexington, United States
University of Louisville Health Brown Cancer Center
Louisville, United States
Norton Cancer Institute
Louisville, United States
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, United States
The Center for Cancer and Blood Disorders
Bethesda, United States
Massachusetts General Hospital
Boston, United States
Beth Israel Deaconess Medical Center
Boston, United States
University of Missouri - Ellis Fischel Cancer Center
Columbia, United States
MidAmerica Cancer Care
Kansas City, United States
Washington University School of Medicine - Siteman Cancer Center
St Louis, United States
Astera Cancer Care
East Brunswick, United States
John Theurer Cancer Center
Hackensack, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Columbia University Irving Medical Center and New York-Presbyterian Hospital
New York, United States
University of Rochester Medical Center
Rochester, United States
Novant Health Cancer Institute- Hematology
Charlotte, United States
Duke Blood Cancer Center
Durham, United States
Oncology Hematology Care - Kenwood
Cincinnati, United States
University of Cincinnati Medical Center
Cincinnati, United States
Cleveland Clinic
Cleveland, United States
Oncology Associates of Oregon
Eugene, United States
Oregon Health and Science University
Portland, United States
Fox Chase Cancer Center
Philadelphia, United States
West Penn Hospital
Pittsburgh, United States
Avera Cancer Institute
Sioux Falls, United States
Vanderbilt University Medical Center
Nashville, United States
Texas Oncology - Central South
Austin, United States
Texas Oncology - Dallas Fort Worth
Dallas, United States
MD Anderson Cancer Center
Houston, United States
Texas Transplant Institute
San Antonio, United States
Texas Oncology - Tyler
Tyler, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, United States
Intermountain Health LDS Hospital
Salt Lake City, United States
University of Virginia
Charlottesville, United States
Virginia Cancer Specialists
Fairfax, United States
Virginia Oncology Associates - Norfolk
Norfolk, United States
Swedish Cancer Institute
Seattle, United States
Fred Hutchinson Cancer Center
Seattle, United States
Icon Cancer Centre Wesley
Auchenflower, Australia
Royal Hobart Hospital
Hobart, Australia
Monash Health
Clayton, Australia
St. Vincent's Hospital Melbourne
Fitzroy, Australia
Austin Health
Heidelberg, Australia
Hollywood Private Hospital
Nedlands, Australia
Arthur JE Child Comprehensive Cancer Centre
Calgary, Canada
Queen Elizabeth II Health Sciences Centre
Halifax, Canada
Princess Margaret Cancer Centre - University Health Network
Toronto, Canada
Centre Integre Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont
Montreal, Canada
CHUM - University of Montreal Hospital Centre
Montreal, Canada
Hopital de'L'Enfant-Jesus
Québec, Canada
Pusan National University Hospital
Seogu, South Korea
Samsung Medical Center
Gangnam-gu, South Korea
Seoul National University
Jongno-gu, South Korea
Asan Medical Center
Songpa-gu, South Korea
Trial contact
Allogene Therapeutics, Inc
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.